Jérémie Bouet

Hemarina SA. is a privately held biotechnology company focused on the research, and development of oxygen-carriers for medical applications.Dr. Franck Zal, an expert in the field of invertebrate hemoglobin and oxygen transport, founded Hemarina after having spent more than fourteen years in academic research centers (CNRS, University ofCalifornia at Santa Barbara USA and University of Antwerpen, Belgium) studying the relationships between the structure and function of invertebrate respiratory pigment (annelid’s extracellular hemoglobin and crustacean hemocyanin). The discoveries arising from his research on extracellular hemoglobin coming from marine invertebrates and their effective oxygen transport system have been patented and published in numerous scientific journals and form the basis of Hemarina’s technologies.Hemarina’s approach to the development of oxygen transport agents is based on the observation of marine worms colonizing extreme environments and the study of their respiratory adaptations.Hemarina’s lead product, HbAm, is designed to deliver oxygen effectively and efficiently to tissues at risk of oxygen deprivation. Hemarina has already a passed panel of strong proof of concepts obtained during preclinical trials.